Author: Funaro, Ada; Gribaudo, Giorgio; Luganini, Anna; Ortolan, Erika; Lo Buono, Nicola; Vicenzi, Elisa; Cassetta, Luca; Landolfo, Santo; Buick, Richard; Falciola, Luca; Murphy, Marianne; Garotta, Gianni; Malavasi, Fabio
Title: Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells Document date: 2008_11_12
ID: 1u2fkwx3_5
Snippet: Agonists of TLR9 have been reported to improve EBV infectivity and cloning efficiency [12] . However, it is known that TLR9 agonists, such as CpG ODN 2006, protect against a wide range of viral pathogens [18] [19] [20] . With this in mind, we reasoned that the presence of CpG during the EBV infection might exert negative effects and we decided to separate activation and EBV infection in two sequential phases. We developed a technology for raising.....
Document: Agonists of TLR9 have been reported to improve EBV infectivity and cloning efficiency [12] . However, it is known that TLR9 agonists, such as CpG ODN 2006, protect against a wide range of viral pathogens [18] [19] [20] . With this in mind, we reasoned that the presence of CpG during the EBV infection might exert negative effects and we decided to separate activation and EBV infection in two sequential phases. We developed a technology for raising human mAbs for clinical applications based on two discrete steps (SEQUENTIAL, Figure 1 ): first, purified human B-lymphocytes are treated with CpG2006 and IL-2. Next, after both additives are removed, the activated cells are infected with EBV in a distinct step. The new process was compared to a method using CpG2006 and IL-2 in the presence of EBV [12] (COMBINED) and a method using
Search related documents:
Co phrase search for related documents- clinical application and negative effect: 1
- CpG presence and EBV infectivity: 1
Co phrase search for related documents, hyperlinks ordered by date